Conference Exhibitors

Bio-Diagnostics Ltd. is a UK-based diagnostics provider supporting NHS and private healthcare services for over 40 years.
Our core expertise sits within allergy diagnostics, where we support NHS departments with comprehensive Type I allergy testing that informs asthma and respiratory care pathways. By enabling accurate identification of allergic triggers, our services help clinicians optimise treatment decisions through accurate diagnosis resulting in improved patient outcomes.

Bio-Diagnostics is expanding its respiratory-focused offering through a new partnership with Bosch Healthcare. We are delighted to be representing the 'Vivatmo FeNO system' for UK and Ireland, which is clinically validated solution for measuring airway inflammation in asthma. The platform supports both clinic-based and home monitoring, enabling personalised, data-led asthma management while reducing the need for repeated face-to-face appointments.
FeNO home monitoring has demonstrated excellent usability, high patient adherence, and strong clinician confidence, supporting its integration into community and digitally enabled care models. This aligns closely with NHS priorities around prevention, remote monitoring, and proactive long-term condition management.

Bio-Diagnostics is keen to collaborate with NHS respiratory and allergy teams, ICS partners, and service providers to support pathway development, service transformation, and innovation across integrated care systems.

Cipla has been developing respiratory medicines for patients for more than 40 years and is committed to becoming a global leader in respiratory care. We have a range of high-quality respiratory products, designed with similar instructions and features to the market-leading originator brands. At Cipla, we have priced our range to be sustainable and affordable so more NHS patients can receive optimal care. We are dedicated to minimising our environmental footprint in support of the NHS goal of becoming carbon net zero by 2040.

CIPCOR20260002 February 2026

Intermedical Cardio Respiratory is a UK-based specialist provider of cardio-respiratory diagnostic and therapy equipment. Established in 1997 and headquartered in Aylesford, Kent, Intermedical supplies innovative respiratory healthcare solutions to NHS organisations, healthcare professionals, and private-sector customers. Intermedical is an ISO 13485 certified NHS approved supplier.
Key products areas include, Spirometry systems and consumables, FeNO testing for asthma diagnosis and management, ECG and ambulatory blood pressure monitoring, Sleep diagnostics, Smoking cessation solutions, Respiratory therapy and monitoring equipment and Remote patient monitoring technologies.

NSHI are an independent leading health services provider who delivers improved patient outcomes in primary, secondary and remote healthcare.

Our specialist clinical services use innovative technology to support healthcare communities to drive quality improvements, and implement NHS Strategies effectively and efficiently.

Collaborating closely with the NHS, pharmaceutical companies and private sector clients, we develop impactful solutions that address health challenges.

About us: Neon is a leading UK-based diagnostics company with a strong track record of supporting the NHS. With extensive experience in providing essential equipment, we play a vital role in the early detection, monitoring, and management of a wide range of diseases. We empower healthcare providers with advanced diagnostic tools designed to improve patient outcomes. Our comprehensive product portfolio supports accurate, efficient testing across a wide range of medical conditions.
- Our mission: High-quality, cost-effective diagnostic equipment supporting accurate, accessible healthcare across the NHS and beyond. Our commitment to ethical innovation and sustainable practices ensures our solutions benefit both people and promote a greener future — making reliable healthcare more affordable and accessible to everyone.
- Out values:
Respect
Teamwork
Quality
Integrity
Innovation

- Respiratory product: FeNOX from Neon Diagnostics, a high performance FeNO device that delivers fast, accurate, and reliable Fractional Exhaled Nitric Oxide measurements to support respiratory assessment and asthma management. Designed for patients aged 6+ in Primary Care, FeNOX combines portability, scalability, and ease of use to provide accessible, cost-effective FeNO testing and efficient clinical workflows.
The clinical and operational advantages of FeNOX include:
• Full CE Marking and MHRA approval.
• Dual patented filtration system to prevent cross infection.
• Offers readings down to 0.1 ppb.
• Simple and easy to use, real time testing for almost instant result capabilities in the form of a game (paediatric option shortens the test time).
• Visually ergonomic, portable with a 10,000 mAh battery and a massive 10-inch HD touchscreen that visualises the breath flow in real-time.
• Remote software updates and improvements based on HCP feedback.
• Designed to minimise long-term operational expenditure through long-life sensors, sensor-only consumables and zero calibration and routine maintenance requirements.

NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma.

NIOX VERO® provides accurate and reliable results, allowing healthcare
professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings.

The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals.

Overall, NIOX Group plc is the global leader in FeNO testing, with a strong
reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma.

References:
1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1
3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173.
4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
5. NIOX®. Data on File; MKT-DOF-007.

Orion Pharma (UK) Ltd. is a wholly owned subsidiary of Orion Corporation, a pharmaceutical company based in Finland. Our principal role is to represent Orion's pharmaceutical products in the UK across a range of therapy areas including Respiratory, Women’s Health and Neurological Disorders.
In the spirit of the values which are common to all units and employees of the Group, we endeavour to provide innovative medicinal treatments and best quality service to patients, healthcare professionals and the community in the UK, the region we operationally cover.
We are continuously developing new drugs and treatment methods. The core therapy areas of our pharmaceutical R&D are oncology and pain. We collaborate closely with healthcare professionals and leading global research institutions and pharmaceutical companies.
www.orionpharma.co.uk

July 2025/CORP-233(4)

Thornton & Ross, part of the STADA group, focuses on caring for people’s health through a broad portfolio including generics, biosimilars and non-prescription consumer healthcare products as a trusted partner supplying the NHS. STADA sells its products in more than 120 countries, employing over 12,000 people worldwide.

As a global leader in allergy and autoimmune disease diagnostics, we are committed to providing accurate, clinically relevant testing solutions to aid in the proper disease diagnosis and patient management. With more than 550 whole allergens and allergen mixes, and 100 allergen components available our products are documented in more than 6,000 publications and referenced in multiple health guidelines. These may be some of the reasons for ImmunoCAP™ being acknowledged as the gold standard technology for specific IgE blood testing

TidalSense is an innovative respiratory diagnostics company based in Cambridge, UK. We have now launched N-Tidal™ Diagnose - a regulated, secure class 2a medical device diagnostic solution delivered as a service. It combines state of the art hardware (N-Tidal®) with AI-powered diagnostic software to deliver COPD diagnosis at the point of care within minutes.

Leveraging a revolutionary new patented sensor technology, N-Tidal® Diagnose performs real-time geometric analysis of CO2 breath waveforms to provide highly sensitive quantification of lung function, from relaxed breathing.

Vitalograph